Abstract:Objective To analyze the effect of bevacizumab on D-dimer (D-D), fibrinogen (FIB) and arteriovenous thromboembolism in the treatment of advanced colorectal cancer (aCRC). Methods A retrospective analysis was performed on the clinical data of 96 patients with aCRC treated in Jiangdu People's Hospital from January 2017 to December 2021. The patients were divided into control group [received XELOX regimen (capecitabine and oxaliplatin), n=48] and observation group (received bevacizumab treatment on the basis of XELOX regimen, n=48). The objective response rate (ORR), disease control rate (DCR), levels of serum tumor markers, serum D-D and FIB, the incidence of arteriovenous thromboembolism and the total incidence of toxic and side effects were compared between two groups. Results Compared with control group, ORR (52.08% vs 29.17%) and DCR (83.33% vs 56.25%) were significantly increased in observation group (P＜0.05＝. Serum levels of carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) in observation group were statistically lower than those in control group after 1, 3 and 6 cycles of chemotherapy (P＜0.05＝. After 1 and 3 cycles of chemotherapy, serum D-D and FIB were similar in two groups (P＞0.05), and they were significantly higher in observation group than those in control group after 6 cycles of treatment (P＜0.05＝. There was no significant difference in the incidences of arteriovenous thromboembolism (8.33% vs 0, P＞0.05) and toxic side effects between observation group and control group (P＞0.05). Conclusion On the basis of conventional chemotherapy for advanced colorectal cancer, the addition of bevacizumab can effectively improve the ORR and DCR of CRC patients, reduce the serum levels of tumor markers and have little impact on serum D-D and FIB levels at the beginning of chemotherapy.